Sai Life Sciences's total inventories for the quarter that ended in Mar. 2026 was ₹1,510 Mil. Sai Life Sciences's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹755 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sai Life Sciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹-24.79.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sai Life Sciences's Days Inventory for the
three
months ended in Mar. 2026 was 19.77.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sai Life Sciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 4.62.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sai Life Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.13.
Sai Life Sciences (NSE:SAILIFE) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Sai Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sai Life Sciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Sai Life Sciences Total Inventories Related Terms
Sai Life Sciences Total Inventories Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Sai Life Sciences (NSE:SAILIFE) has a Total Inventories of ₹1,510 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sai Life Sciences and its competitors.
Is Sai Life Sciences' Total Inventories too high?
Sai Life Sciences' current Total Inventories is ₹1,510 Mil. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Total Inventories compare to TMO and DHR?
Sai Life Sciences' Total Inventories of ₹1,510 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sai Life Sciences and its competitors. Sai Life Sciences's current Total Inventories is ₹1,510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Total Inventories of ₹1,510 Mil. The current Total Inventories is ₹1,510 Mil. Sai Life Sciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Total Inventories is ₹1,510 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
